Evogene Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVGN research report →
Range $2.15 – $2.15
Price Chart
About the company
Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components.
- CEO
- Ofer Haviv
- IPO
- 2010
- Employees
- 52
- HQ
- Rehovot, HM, IL
Get TickerSpark's AI analysis on EVGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.72M
- P/E
- -0.32
- PEG
- 0.00
- P/S
- 1.97
- P/B
- -1.11
- EV/EBITDA
- 0.39
- Div Yield
- 0.00%
- Gross Margin
- -14.16%
- Op Margin
- -1020.35%
- Net Margin
- -696.26%
- ROE
- 761.97%
- ROIC
- -113.67%
Latest fiscal year · YoY change
- Revenue
- $3.85M-30.9%
- Gross Profit
- $-241,000-107.5%
- Op Income
- $-14,034,000
- Net Income
- $-8,485,000+48.5%
- EPS
- $-1.08+62.6%
- OCF Growth
- +31.5%
- FCF Growth
- +32.9%
- 52W High
- $1.26
- 52W Low
- $0.25
- 50D MA
- $0.40
- 200D MA
- $0.62
- Beta
- 0.68
- RSI (14)
- 41
- Avg Volume
- 1.42M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evogene highlighted early progress in two internally funded programs—an acute GVHD drug and a Septoria fungicide—while reporting lower revenue, a $10.5 million nine-month net loss, and $9.2 million in cash at quarter-end.· November 19, 2026
- ChemPass AI helped generate novel, patentable small molecules for acute GVHD with nanomolar potency and promising early ADME/tox signals.
- AgPlenus reported fungicide candidates against Septoria, including molecules that reduced disease severity by 75% in infected plant tissue.
- Management said the pharma program could enter preclinical trials around mid-2027, after which it hopes to start engaging pharma partners.
- Cash and short-term bank deposits were $9.2 million at September 30, 2026; third-quarter cash usage was $2.4 million.
- Revenue fell as Bayer-related collaboration revenue ended and Casterra had weaker sales versus last year.
As of September 30, 2026, Evogene held approximately $9.2 million in consolidated cash, cash equivalents and short-term bank deposits. Third-quarter consolidated cash usage was approximately $2.4 million, including a $0.5 million Directors’ and Officers’ insurance payment covering an 18-month period. Revenues for the first 9 months of 2026 were approximately $0.8 million, down from approximately $3.2 million in the same period of 2025; third-quarter revenue was approximately $0.1 million versus approximately $0.3 million a year earlier. R&D expenses, net of non-refundable grants, were approximately $4.5 million for the first 9 months of 2026 versus $4.6 million last year, and approximately $1.5 million in Q3 2026 versus $1.1 million in Q3 2025. Net loss for the first 9 months of 2026 was approximately $10.5 million versus approximately $2.5 million in the prior-year period; Q3 2026 net loss was approximately $2.9 million versus net income of approximately $5.2 million in Q3 2025. Management did not give quantitative revenue or earnings guidance; instead, it said the pharma program could enter preclinical trials around mid-next year, while the Septoria program should move into greenhouse and later field trials next year.
Ofer Haviv framed the quarter around building proprietary assets using Evogene’s AI discovery platform, emphasizing that both the aGVHD and Septoria programs validate ChemPass AI’s ability to create novel molecules with commercial potential. He said the company is still early in discovery, but the speed of progress and the quality of the molecules give confidence in the platform. His tone was constructive and upbeat, especially on the possibility of future partnering once preclinical data are available.
Polina Ravzin focused on the financial decline in revenue and the main drivers behind the year-over-year changes. She said lower revenue was mainly due to reduced Casterra sales and the end of the Bayer license and collaboration agreement in May 2026, while R&D stayed relatively stable at approximately $4.5 million for the first 9 months. She also highlighted financing expense volatility tied to warrant accounting, including approximately $3.8 million of financing expenses from the February 2026 warrant inducement transaction and approximately $2.3 million of financing income from warrant revaluation as of September 30, 2026. Cash stood at approximately $9.2 million, and quarterly cash use was approximately $2.4 million.
An analyst asked when Evogene might out-license or partner its pharmaceutical compounds, how the timeline differs between pharma and ag programs, and whether there was movement in the disclosed pipeline during Q3. Haviv said the pharma program is just beginning synthesis validation and could reach preclinical trials around mid-next year, after which the company would start approaching pharma companies. He added that ag programs can be validated on crop earlier with less regulatory friction than human drug programs, so confidence is higher when entering the more expensive regulatory phase. On the broader pipeline, he said the call was focused on internal programs and that collaboration progress would be covered in a future company presentation.
The company presented real scientific progress in two internal programs, including nanomolar aGVHD candidates and Septoria fungicide molecules with a reported 75% disease-severity reduction in plant tissue. Management also said there is initial interest from potential partners in novel Septoria solutions, and Haviv sounded optimistic that the programs could create partnering opportunities as data mature.
Revenue remains very small and declined sharply year over year, while net loss widened to approximately $10.5 million for the first 9 months of 2026. The pharma program is still at an early discovery stage, with preclinical timing only projected for around mid-next year, so monetization remains distant. The business also continues to show financial noise from warrant-related accounting and non-recurring legal/corporate governance costs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 106.9%
- Shares Outstanding
- 8.62M
- Float Shares
- 9.21M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eidelman Virant Capital | 117.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Adler Oz | other | 0 |
| Oct 6, 26 | Zuloff-Shani Adi | other | 0 |
| Sep 4, 26 | RECANATI LEON | other | 2,500 |
| Sep 4, 26 | Nimrodi Nir | other | 10,000 |
| Sep 4, 26 | Percy Adrian John | other | 2,500 |
| Sep 4, 26 | Falk Dan Michael | other | 2,500 |
| Jun 4, 26 | Tarcic Gabi | buy | 1,129 |
| Aug 11, 26 | RECANATI LEON | buy | 460,000 |
| Aug 4, 26 | RECANATI LEON | buy | 800,000 |
| Apr 1, 26 | Ravzin Polina | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVGN coverage
Recent articles, reports, and earnings notes.
No research on EVGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EVGN report →EverGen Infrastructure Corp. (EVGN:CA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 19
Evogene Ltd. (EVGN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 19
Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs
prnewswire.com · Nov 19
EverGen Infrastructure Reports Q3 2026 Improved Results
businesswire.com · Nov 18
AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
prnewswire.com · Nov 17
Coya Therapeutics (NASDAQ:COYA) vs. Evogene (NASDAQ:EVGN) Head to Head Review
defenseworld.net · Nov 15
Evogene Schedules Third Quarter 2026 Financial Results Release
prnewswire.com · Nov 5
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
prnewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.